Search clinical trials for: somapacitan

Total 20 results

Novo Nordisk A/S

Completed

First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects

Healthy | Growth Hormone Disorder | Growth Hormone Deficiency in Children | Adult Growth Hormone Deficiency

Germany
Novo Nordisk A/S

Completed

Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function

Growth Hormone Disorder | Growth Hormone Deficiency in Children | Adult Growth Hormone Deficiency

Germany
Novo Nordisk A/S

Completed

A Study to Compare the Uptake Into the Blood of Two Strengths of Somapacitan After Injection Under the Skin in Healthy Subjects

Healthy Volunteers | Growth Hormone Deficiency

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Absorption, Metabolism and Excretion of Somapacitan After Single Dosing in Healthy Male Subjects

Healthy

Netherlands
Novo Nordisk A/S

Completed

Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function.

Growth Hormone Disorder | Growth Hormone Deficiency in Children | Adult Growth Hormone Deficiency

Slovakia
Novo Nordisk A/S

Recruiting

A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9 (REAL 9)

Turner Syndrome | Noonan Syndrome | SGA | ISS

Korea, Republic of, Malaysia, Netherlands, Spain, Poland, United States
Novo Nordisk A/S

Recruiting

A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow (REAL 8)

SGA, Turner Syndrome, Noonan Syndrome, ISS

Belgium, Korea, Republic of, United States, Ireland, Malaysia, United Kingdom, Finland, France, Netherlands, Thailand, China, Japan, Portugal, Israel, Brazil, India, Austria, Bulgaria, Canada, Croatia, Germany, Greece, Italy, Poland, Saudi... and more
Novo Nordisk A/S

Completed

A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency (REAL 2)

Growth Hormone Disorder | Adult Growth Hormone Deficiency

Denmark, France, Germany, Japan, Sweden, United Kingdom
Novo Nordisk A/S

Active, not recruiting

A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day

Short Stature Children Born Small for Gestational Age (SGA)

France, Russian Federation, United States, India, Spain, Estonia, Japan, Italy, Algeria, Austria, Hungary, Ireland, Israel, Latvia, Poland, Serbia, Thailand, Ukraine
Novo Nordisk A/S

Recruiting

Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not Closed

Growth Hormone Deficiency in Children

Japan
Novo Nordisk A/S

Enrolling by invitation

A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information

Adult Growth Hormone Deficiency

United States, Saudi Arabia, Germany, Slovenia
Novo Nordisk A/S

Completed

A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency

Growth Hormone Disorder | Adult Growth Hormone Deficiency

Japan
Novo Nordisk A/S

Completed

A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency

Growth Hormone Disorder | Growth Hormone Deficiency in Children

France, Israel, Austria, Spain, Switzerland, North Macedonia, Norway, Slovenia, Belgium, Sweden
Novo Nordisk A/S

Completed

Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency. (REAL 1)

Growth Hormone Disorder | Adult Growth Hormone Deficiency

United States, Poland, India, Japan, Russian Federation, United Kingdom, Germany, Sweden, Israel, Malaysia, Turkey, South Africa, Australia, Latvia, Lithuania, Romania, Brazil, Norway, Ukraine
Novo Nordisk A/S

Active, not recruiting

A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4) (REAL4)

Growth Hormone Deficiency in Children

United States, Korea, Republic of, United Kingdom, Canada, Russian Federation, India, Spain, Italy, Algeria, Austria, France, Ireland, Israel, Japan, Latvia, Poland, Serbia, Thailand, Ukraine, Germany, Slovenia, Switzerland
Novo Nordisk A/S

Completed

A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.

Growth Hormone Deficiency in Children

China
Novo Nordisk A/S

Enrolling by invitation

Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®

Adult Growth Hormone Deficiency

Japan
Novo Nordisk A/S

Recruiting

Investigating Efficacy and Safety of Once-weekly NNC0195-0092 (Somapacitan) Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency

Growth Hormone Disorder | Growth Hormone Deficiency in Children

United States, Japan, Israel, India, Austria, Slovenia, Belgium, Brazil, France, Germany, Sweden, Turkey, Ukraine
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency

Growth Hormone Disorder | Adult Growth Hormone Deficiency

Denmark, Sweden
AstraZeneca

Completed

A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure

Raised Intraocular Pressure

Sweden, United States, United Kingdom

3

Subscribe